Table 1. Characteristics of general practices, N = 6251.
|
Mean, entire study population,2014–2015 & 2015–2016,% (95% CI) |
Mean, period before QP,2014–2015,% (95% CI) | Mean, period after QP,2015–2016,% (95% CI) | Mean, top 20% of prescribing practices,2014–2015 & 2015–2016,% (95% CI) | |
|---|---|---|---|---|
| Antibiotic items per STAR-PU | 1.057(1.055 to 1.059) | 1.106(1.103 to 1.108) | 1.009(1.007 to 1.011) | 1.357(1.354 to 1.360) |
| Asthma prevalenceper 100 patients | 5.941(5.935 to 5.947) | 5.980(5.971 to 5.989) | 5.901(5.893 to 5.911) | 6.295(6.281 to 6.309) |
| COPD prevalenceper 100 patients | 1.878(1.873 to 1.882) | 1.861(1.855 to 1.867) | 1.894(1.888 to 1.900) | 2.301(2.291 to 2.312) |
| Cancer prevalenceper 100 patients | 2.346(2.342 to 2.350) | 2.264(2.258 to 2.270) | 2.428(2.421 to 2.434) | 2.230(2.291 to 2.309) |
| CKD prevalenceper 100 patients | 4.129(4.119 to 4.139) | 4.143(4.129 to 4.157) | 4.115(4.101 to 4.129) | 4.420(4.398 to 4.442) |
| Diabetes prevalenceper 100 patients | 6.635(6.626 to 6.645) | 6.544(6.532 to 6.557) | 6.726(6.713 to 6.740) | 7.316(7.298 to 7.335) |
| Opioids prescriptionper 100 patients | 3.273(3.265 to 3.282) | 3.241(3.229 to 3.253) | 3.306(3.293 to 3.318) | 4.306(4.285 to 4.328) |
| Benzodiazepineanxiolytics prescriptionper 100 patients | 0.917(0.914 to 0.919) | 0.920(0.916 to 0.924) | 0.913(0.910 to 0.917) | 1.151(1.145 to 1.158) |
| Benzodiazepinehypnotics prescriptionper 100 patients | 1.311(1.308 to 1.315) | 1.333(1.328 to 1.338) | 1.289(1.284 to 1.294) | 1.673(1.664 to 1.682) |
| GP workforceper 10 000 patients | 6.126(6.112 to 6.139) | 6.429(6.412 to 6.446) | 5.822(5.802 to 5.842) | 5.835(5.805 to 5.864) |
CKD = chronic kidney disease. COPD = chronc obstructive pulmonary disease. QP = Quality Premium. STAR-PU = specific therapeutic group age–sex related prescribing unit.